FCN-338

FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC50 of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL[1][2].

Product Specifications

CAS Number

[2248046-39-9]

Product Name Alternative

LOXO-338

UNSPSC

12352005

Target

Bcl-2 Family

Related Pathways

Apoptosis

Field of Research

Cancer

Smiles

ClC1=CC=C(C=C1)C(CC(C)(CC2)C)=C2CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(OC6)=C(C([N+]([O-])=O)=C5)N[C@H]6CC7=CC=CC=C7)=O)=O)C(OC8=CN=C9NC=CC9=C8)=C4)CC3

Molecular Formula

C48H48ClN7O7S

Molecular Weight

902.46

References & Citations

[1]Brandhuber B, et al. Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor[J]. Cancer Research, 2021, 81 (13_Supplement) : 1258-1258.|[2]Vogler M, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025 Mar 21;10 (1) :91.